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Conclusions: TAVI has provided good results in the
initial 27 patients. However, The use of transcatheter aor-
tic valve implantation should be restricted to the inoper-
able high-risk patients.
http://dx.doi:10.1016/j.jsha.2013.03.071
Downs syndrome and cardiac surgery, a dilemma,
should we operate or not?
Ghada Shiekh Abdullah, Shehla Jadoon,
Milad Elsegaier, M.O. Galal
Background: Incidence of congenital heart disease
in patients with Down syndrome (DS) is 40%. In the
past some have advocated that the cardiac defects in
DS should not be repaired, reports had shown outcome
comparable to individuals without DS. The aim of the
study is to analyze the outcome of cardiac surgery in
DS.
Methodology: We conducted a retrospective study
in the last 2 years at our institution. Patients involved
were DS less than 13 years who had cardiac surgery.
DS with chronic lung disease or unreactive pulmonary
hypertension were excluded. We analyzed their demo-
graphic data, cardiac lesion, type of surgery, ICU stay,
morbidities and mortality.
Results: 23 patients with DS (11 Females, 13 Males),
with median age of 7 months, mean age of 32month.
AVSD were (n = 15) 65%), VSD were (n = 5) 21%. Postop-
eratively, 21% were extubated on the same day. 27% had
intubation more than 9 days. Almost 30% had a hospital
stay of >15 days. Complications were respiratory prob-
lems in 45%, arrhythmias in 8% and residual AV valve
regurgitation in 8%. Hospital mortality was (n = 2/23) 8%.
Conclusion: Whether to operate Down syndrome
patients or not remains unclear. Our study showed, sig-
nificant postoperative complications, lengthy hospital
stay and relatively high mortality. Despite of this we feel
they should be given the chance of surgery to improve
their life quality.
http://dx.doi:10.1016/j.jsha.2013.03.072
Utilization of prophylactic drug therapy after acute
myocardial infarction in Abu Dhabi and Sweden
Oliver Harrison, Khaled Aidha Al Jaberi, Eman S.
Hassan, Björn Wettermark, Ana-Marija Gjurovic,
Gunnar Engström
Purpose: Pharmaceutical treatments to decrease
blood pressure and lipids, inhibit platelet aggregation,
and control diabetes are cornerstones of secondary pre-
vention after acute myocardial infarction (AMI). This
study compares the drug use during a oneyear period
post-AMI in Abu Dhabi and Sweden.
Methods: In Abu Dhabi, information on medications
dispensed during one year following a hospitalized AMI
during January 2010 to June 2011 (n = 1,326) was retrieved
from the Health Authority of Abu Dhabi’s administrative
claims database. Rates of at least one prescription within
selected classes were quantified immediately following
the event (months 0–3), 4–6 months, and 10–12 months
after the event. Similar data was collected for hospital-
ized AMI patients in Sweden during 2009 (n = 19,312),
by linkage of the Swedish Myocardial Infarction register
and Prescribed Drug Register. All proportions were age-
standardized.
Results: During the first three months post-AMI, the
proportion of patients in Abu Dhabi with at least one pre-
scription of an anti-hypertensive drug was 76%, statin
72%, platelet aggregator inhibitor 76%, beta-blocker
64%, and drugs affecting the renin-angiotensin system
only 56%. These proportions declined to 36%, 34%, 34%,
28% and 28%, respectively, during month 10-12. Reduc-
tions among UAE citizens were somewhat lower than
among expatriates. In Sweden, the corresponding pro-
portions were 90%, 82%, 89%, 83% and 68%, respectively,
10- 12 months post-AMI.
Conclusion: Abu Dhabi’s health data systems offer a
valuable tool for monitoring adherence to drug use. It
appears that the outcomes of AMI patients in Abu Dhabi
could be substantially improved by promoting adherence
to evidence-based guidelines for secondary prevention.
http://dx.doi:10.1016/j.jsha.2013.03.073
Systemic lupus erythrematosus; its implication in
cardiac surgery: Institutional case report
Hala Samir El-Mohamady ⇑
Introduction: Systemic lupus erythematosus (SLE)
is an autoimmune disease that primarily affects young
women. According to the literature, the prevalence of
cardiovascular involvement in patients with systemic
lupus erythematosus (SLE) has been estimated to be
more than 50%.
Valvular involvement is the most frequent cardiac
manifestation in SLE. Functionally, valvular regurgitation
hasbeen reported to occur in up to 74% of patients.
Meanwhile valvular endocarditis is a frequent manifesta-
tion of SLE, and the mitral valve is most frequently
affected. However, any valve or multivalvular affection
may occur.
Valvular lesions resulting from lupus can cause severe
mitral regurgitation (MR). The most classic cardiac
valvular abnormality in patientswith SLE is known as
Libman–Sacks endocarditis, which consists of
noninfective, verrucousvegetations(marantic endocardi-
tis). They occur most frequently onthe mitral valve. Most
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of the valves that have vegetations are usually associated
with diffuse thickeningor regurgitation.
However, although cardiac involvement in patients
with SLE has been recognized since the early 20th, But
cardiac surgery was infrequently performed in patients
with SLE, and its clinical outcome was reported only in
small series. Also the impact of SLE on provision of anes-
thesia has never beeninvestigated, and the lack of evi-
dence combined with theheterogeneity of disease
manifestations makes it difficult toestablish definitive
management protocols.
That’s why, We herein describe a 22 years old female
patient with SLE,with end stage renal diseaserequiring
peritoneal dialysis. presented to our hospital (Al-Demer-
dash, Ain Shams University Hospital), with signsof
congestiveheart failure such as dyspnea on exertion
andorthopnea, paroxysmal nocturnal dyspnea, and
fatigue, refractory to medical management.Her therapy
for SLE required longterm prednisolonand hydroxy-
chloroquine.
Physical examination revealed no facial malar rash or
generalized discoid rashes. The breath sounds were
diminished at the lower lung zones. Cardiac auscultation
showed regular heart beat with a heart rate of 102 beats/
min, a grade III/VI systolic murmur at the left lower ster-
nal border and the apex, and a pericardial friction rub.
Palpation of the abdomen showed hepatomegaly. The
extremities were notable for mild pitting edema. There
was no clubbing, cyanosis or deformity of joints.
Preoperative data: Complete blood count revealed
Hg 9.9 g/dl, WBC 11.100/ul, Platelet 247,000/ul. Bleeding
Profile showed PT 16.4 sec, INR 1.45, PTT 44 sec. biochem-
istry work-up showed, Glucose 75 mg/dl, Creat 2.9 mg/dl
with hemodialysis session, ALT 15U/l, AST 20U/l.
Preoperative transesophageal Echocardiography
showed: A large mass is attached to the atrial surface of
the anterior mitral leaflet measuring 6  7 mm. the mass
perforates the leaflet causing severe mitral regurgitation.
And, another large mass measuring 6  9 mm attached to
the non-coronary aortic valve cusp with 2 small masses
attached to each of the other two leaflets causing severe
aortic regurgitation.EF 60%,RVSP 50 mmHg.
So the patient was scheduled for double valve replace-
ment. Although valve repair and bioprosthetic valve
replacement are not the best solution, since accelerated
native valve and bioprosthetic valve calcification tend to
occur because of the high calcium turnover. Also Porcine
valves have become affected by valvulitiswith perforation
of valve cusps.
But, our cardiac surgical team decided to replace
mitral and aortic valve with bioprothetic valve, as they
believe that Anticoagulation may present higher risks
in our young patient who require prolonged steroid use
and who have end stage renal failure, the resultant
dependence on dialysis. Also previous reports described
patients with SLE who underwent mitral valve replace-
ment, had a number of complications, and died second-
ary to anticoagulation. Also, because ofsuccessful
placement of the porcine Carpentier-Edwards biopros-
thesis in patients with SLE has been reported before.
Finally weaning from cardiopulmonary bypass was
uneventful (adrenaline 50 n/kg/min). The patient’s recov-
ery from surgery was uncomplicated, and she was dis-
charged on the 6th postoperative day.
In conclusion, although the postoperative complica-
tion is common, cardiac operation could be performed
in patients with SLE.
http://dx.doi:10.1016/j.jsha.2013.03.074
Direct aortic transcatheter aortic valve implanta-
tion, a promising new approach
Hasan Sami Bushnaq, Michael Buerke,
Christoph Raspé, Rolf-Edgar Silber, Dietrich Metz
Objective: The transcatheter aortic valve implanta-
tion (TAVI) is an established therapy option for high risk
patients with severe aortic valve stenosis. The peripheral
arterial (Femoral or Subclavien) and the minimal invasive
surgical access via Apex are the standard access routes.
Out come and prognosis of TAVI is determined by the
peripheral vessel complications, strokes, paravalvular
leak and apical cardiac infarction. The direct aortic (DA)
approaches is a new alternative for the minimal invasive
surgical TAVI access. We report our experience and dis-
cuss the different aspects this technique.
Methods: Between September 2011 and August 2012
we performed in 50 patients DA-TAVI via partial upper
sternotomy with the self expanding Medtronic CorValve
bioprothesis. From the tenth patient DA was the primary
access route for TAVI. The Procedure is done in general
anesthesia and performed by an interventional heart
team in the operating room (OR). The fast-track anesthe-
sia with immediate extubation after the procedure in the
OR was established after the tenth patient.
Results: Themeanpatients agewas 78 ± 5,2 years and
52% were male. The mean logistic EuroSCORE were
20,3 ± 10,8. Coronary artery disease were documented in
30 (60%) patients, including eight re-do procedures. In 15
(30%) cases were severe peripheral vasculopathy themain
indication for DA access. Procedural success was 100%.
Mean aortic gradient dropped immediately under 5 mm
Hg, end diastolic left ventricle pressure improved on aver-
age by 30% in all patients and there was no vascular com-
plications. Stroke occurred in one patient. 5 patients had,
during the first days after the procedure, a psycho-organic
syndrome, where a stroke was excluded. The post-opera-
tive echocardiogram demonstrated in 45 (90%) patients
non to trace, in 4 (8%) patients mild and in 1(2%) patient
moderate aortic regurgitation.
Conclusion: Direct aortic access for TAVI is a surgi-
cal simple, flexible and safe approach to treat high risk
patients with symptomatic aortic stenosis and might
enrich the surgical TAVI access with a new promising
approach.
http://dx.doi:10.1016/j.jsha.2013.03.075
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